1. Home
  2. LENZ

as of 08-20-2026 2:08pm EST

$4.59
$0.33
-6.81%
Stocks Health Care Medicinal Chemicals and Botanical Products Nasdaq

LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.

Founded: 2019 Country:
United States
United States
Employees: N/A City: SOLANA BEACH
Market Cap: 155.5M IPO Year: 2021
Target Price: $44.00 AVG Volume (30 days): 817.7K
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.34 EPS Growth: -21.79
52 Week Low/High: $4.54 - $50.19 Next Earning Date: 05-06-2026
Revenue: $19,088,000 Revenue Growth: N/A
Revenue Growth (this year): 50.42% Revenue Growth (next year): 197.16%
P/E Ratio: -2.10 Index: N/A
Free Cash Flow: -69997000.0 FCF Growth: N/A

AI-Powered LENZ Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 19 hours ago

AI Recommendation

hold
Model Accuracy: 71.28%
71.28%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q2

Q2 2026 Earnings

8-K BUY

Aug 11, 2026 · 100% conf.

AI Prediction BUY

1D

+0.91%

$5.24

Act: -2.70%

5D

+10.59%

$5.74

Act: -8.09%

20D

+9.08%

$5.66

Price: $5.19 Prob +5D: 100% AUC: 1.000
0001815776-26-000051

EX-99.1

2 a991q226pressrelease.htm

EX-99.1

Document

Exhibit 99.1

LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Q2 2026 total revenue of $5.5 million from VIZZ product sales and global license agreements

Strong patient persistence, with over 60% of patients in our dominant ePharmacy channel purchasing multiple monthly packs since launch, tracking to five packs annually

VIZZ prescription growth accelerated with launch of telehealth channel in July 2026

Management to host conference call today, August 11, 2026, at 4:30 p.m. EDT

SAN DIEGO, CA – August 11, 2026 – LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia, today reported financial results for the second quarter ended June 30, 2026, and recent corporate highlights.

“We are encouraged by the early refill behavior we are seeing with VIZZ. The majority of ePharmacy patients have purchased multiple monthly packs since launch, and among those patients, our Q4 2025 and Q1 2026 cohorts are tracking to average annualized utilization of five packs per patient. These trends reinforce the value VIZZ is delivering in the real world,” said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics. “Our focus is now on bringing more consumers into the category and making access as seamless as possible. Through telehealth, eligible consumers can be evaluated online by an independent licensed eye care professional and, if prescribed, receive VIZZ at home. Together with our national ‘Tired of Reading Glasses’ campaign, telehealth is designed to more readily convert awareness into adoption. While it is still early, the initial indicators are encouraging, and we believe we are building the foundation for sustained growth driven by consumers.”

Second Quarter 2026 and Recent Corporate Highlights

Commercial Launch

•Q2 2026 product revenues of over $1.7 million on approximately 27,000 packs sold, a 9% increase over Q1 2026.

•Over 60% of ePharmacy patients have purchased more than one monthly pack of VIZZ since launch; encouraging early average projected refill rates from those starting VIZZ in Q4 2025 and Q1 2026 of 5 packs per year.

•Broad uptake by eye care professionals (“ECPs”), with over 13,000 unique prescribers from launch through Q2 2026, with approximately 75% prescribing multiple times.

•In July 2026, launched a telehealth prescribing option to accelerate patient access to VIZZ, offering patients the convenience of an integrated online evaluation by independent licensed eye care providers, e-pharmacy prescription fulfillment and home delivery, in addition to existing access through eye care professionals.

•In July 2026, launched a nationwide TV advertising campaign featuring brand spokesperson Sarah Jessica Parker.

Advancing Global Commercialization Strategy and Expanding International Partnerships

•In April 2026, LENZ submitted a Marketing Authorization Application (“MAA”) to the United Kingdom's Medicines and Healthcare products Regulatory Agency (“MHRA”) for the review

and approval of VIZZ for the treatment of presbyopia in adults. The MHRA submission followed validation of the VIZZ MAA by the European Medicines Agency in March 2026.

•In June 2026, LENZ announced an exclusive license and commercialization agreement with Arrotex Pharmaceuticals to register and commercialize VIZZ for the treatment of presbyopia in Australia and New Zealand, its fifth ex-U.S. commercialization partnership. Under the terms of the agreement, LENZ received an upfront payment and is eligible to receive a mid double-digit profit share of gross margin from product sales in Australia and New Zealand.

•In June 2026, LENZ achieved its first regulatory milestone under the License and Commercialization Agreement with Laboratoires Théa upon the submission of its New Drug Submission to Health Canada for the review and approval of VIZZ for the treatment of presbyopia in adults in Canada. Under the terms of the agreement, LENZ is eligible to receive up to $65 million in remaining regulatory and commercial milestone payments, as well as tiered, double-digit royalties on future net sales in Canada.

•In June 2026, Everest Medicines entered into an Asset Purchase Agreement with CORXEL Pharmaceuticals to acquire the rights to develop, manufacture, and commercialize VIZZ (LNZ100) in Greater China. LENZ is eligible to receive up to $85.0 million in remaining regulatory and sales milestones, as well as tiered mid single-digit to low double-digit royalties on net sales in Greater China. LENZ has received the first of multiple potential milestone payments under this sublicensing arrangement in connection with the execution of the agreement between CORXEL and Everest.

•In July 2026, under the exclusive distribution agree

2026
Q1

Q1 2026 Earnings

8-K SELL

May 11, 2026 · 100% conf.

AI Prediction SELL

1D

-4.01%

$9.59

Act: -20.82%

5D

-2.80%

$9.71

Act: -30.93%

20D

+2.58%

$10.25

Act: -32.03%

Price: $9.99 Prob +5D: 0% AUC: 1.000
0001815776-26-000035

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.e618d017.1784333578.426f2e9e

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

2025
Q4

Q4 2025 Earnings

8-K BUY

Mar 24, 2026 · 100% conf.

AI Prediction BUY

1D

+2.12%

$16.66

Act: -6.56%

5D

+11.40%

$18.17

Act: +13.98%

20D

+13.05%

$18.44

Act: -14.35%

Price: $16.31 Prob +5D: 100% AUC: 1.000
0001815776-26-000008

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.e618d017.1784333580.426f50e7

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

Share on Social Networks: